Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | PRCP | P42785 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6097576 | 1.00 | HTR3A (0.49) | HTR3ALTA4HSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7076362 | 1.00 | HTR3A (0.49) | HTR3ALTA4HSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6098075 | 1.00 | HTR3A (0.49) | HTR3ALTA4HSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7029317 | 0.82 | KDM1A (0.46) | LTA4HSLC6A2SLC6A4SLC6A3TACR1 | |
| SCHEMBL7557471 | 0.82 | KDM1A (0.46) | LTA4HSLC6A2SLC6A4SLC6A3TACR1 | |
| SCHEMBL6669116 | 0.82 | MAPT (0.40) | PRCP | |
| SCHEMBL6074341 | 0.82 | KDM1A (0.46) | LTA4HSLC6A2SLC6A4SLC6A3TACR1 | |
| SCHEMBL7485890 | 0.82 | KDM1A (0.46) | LTA4HSLC6A2SLC6A4SLC6A3TACR1 | |
| SCHEMBL6669110 | 0.82 | MAPT (0.40) | PRCP | |
| SCHEMBL6669105 | 0.82 | MAPT (0.40) | PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7067535-B2 | 5-Phenylbenzylamine compounds, process for their production and intermediates for their synthesis | TANABE SEIYAKU CO., LTD. (JP) | 2006-06-27 | — | — | US | disclosed |
| EP-1457487-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE CIS-PIPERIDINE DERIVATIVES | Toray Fine Chemicals Co., Ltd. (JP) | 2004-09-15 | — | — | EP | disclosed |
| US-20040171836-A1 | Method for producing optical-active cis-piperidine derivatives | TORAY FINE CHEMICALS CO., LTD., A CORPORATION OF JAPAN, (JP) | 2004-09-02 | — | — | US | disclosed |
| US-20040097548-A1 | 5-Phenylbenzylamine compounds, process for their production and intermediates for their synthesis | TANABE SEIYAKI CO., LTD. (JP) | 2004-05-20 | — | — | US | disclosed |
| EP-1323713-A1 | 5-PHENYLBENZYLAMINE COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND INTERMEDIATES FOR THEIR SYNTHESIS | TANABE SEIYAKU CO., LTD. (JP) | 2003-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171836-A1 | Method for producing optical-active cis-piperidine derivatives | TYR, DDC, TARBP1 | HTR3A 666/4885LTA4H 2757/4885SLC6A2 2935/4885 |
| US-20040097548-A1 | 5-Phenylbenzylamine compounds, process for their production and intermediates for their synthesis | CYP1B1, MAOB, HTR1B | HTR3A 141/4885LTA4H 2467/4885SLC6A2 711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.